GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Other Income (Minority Interest)

Ensol Biosciences (XKRX:140610) Other Income (Minority Interest) : ₩0.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences Other Income (Minority Interest)?

Other Income (Minority Interest) represents par value or stated value of the subsidiary stock not owned by the parent company plus the minority interest's equity in the surplus of the subsidiary. Ensol Biosciences's Other Income (Minority Interest) for the six months ended in Dec. 2023 was ₩0.0 Mil. Its Other Income (Minority Interest) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩0.0 Mil.

Ensol Biosciences Other Income (Minority Interest) Historical Data

The historical data trend for Ensol Biosciences's Other Income (Minority Interest) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences Other Income (Minority Interest) Chart

Ensol Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Minority Interest)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ensol Biosciences Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Minority Interest) Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ensol Biosciences Other Income (Minority Interest) Calculation

Other Income (Minority Interest) represents par value or stated value of the subsidiary stock not owned by the parent company plus the minority interest's equity in the surplus of the subsidiary.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Other Income (Minority Interest) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ensol Biosciences  (XKRX:140610) Other Income (Minority Interest) Explanation

Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company. It is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Ensol Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Other Income (Minority Interest)
Comparable Companies
XKRX:251120 XKRX:067370 XKRX:284620 XKRX:308080 XKRX:389030 XKRX:263050 XKRX:086820 XKRX:353810 XKRX:234690 XKRX:378800 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036
Website
http://www.ensolbio.co.kr
Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences Headlines

No Headlines